New combo pill could boost weight loss and fight inflammation

NCT ID NCT07220629

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times

Summary

This study tests whether adding an experimental drug (NT-0796) to semaglutide (a weight-loss medication), along with diet and exercise, helps people with obesity lose more weight and reduce inflammation. About 82 adults with a BMI of 30 or higher will receive either the combination or a placebo for 6 months. The main goals are to check safety and see if the drug lowers body weight and markers of inflammation like hsCRP.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigative Site

    Mesa, Arizona, 85225, United States

  • Investigative Site

    Hialeah, Florida, 33016, United States

  • Investigative Site

    Jacksonville, Florida, 32216, United States

  • Investigative Site

    Miami, Florida, 33147, United States

  • Investigative Site

    Marrero, Louisiana, 70006, United States

  • Investigative Site

    Columbus, Ohio, 43213, United States

  • Investigative Site

    Seabrook, Texas, 77586, United States

  • Investigative Site

    Salt Lake City, Utah, 84124, United States

  • Investigative Site

    Manassas, Virginia, 20110, United States

Conditions

Explore the condition pages connected to this study.